Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection

MT Newswires Live

03/12

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) obtained approval from China's National Medical Products Administration for the clinical trial of SHR-9803 for injection, according to a Shanghai bourse filing on Thursday.

The drug will be tested in combination with Adebrelimab, Bevacizumab and chemotherapy in patients with advanced malignant solid tumors.

The pharmaceutical company's Hong Kong shares slipped over 1% during the afternoon trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618390072"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618390072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618390072?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 14:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618390072","market":"hk","top_or_hot":-1,"title":"Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals (SHA:600276, HKG:1276) obtained approval from China's National Medical Products Administration for the clinical trial of SHR-9803 for injection, according to a Shanghai bourse filing on Thursday.</p><p>The drug will be tested in combination with Adebrelimab, Bevacizumab and chemotherapy in patients with advanced malignant solid tumors.</p><p>The pharmaceutical company's Hong Kong shares slipped over 1% during the afternoon trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-12 14:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals (SHA:600276, HKG:1276) obtained approval from China's National Medical Products Administration for the clinical trial of SHR-9803 for injection, according to a Shanghai bourse filing on Thursday.</p><p>The drug will be tested in combination with Adebrelimab, Bevacizumab and chemotherapy in patients with advanced malignant solid tumors.</p><p>The pharmaceutical company's Hong Kong shares slipped over 1% during the afternoon trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2543165471.USD","symbol_name":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618390072","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618390072","pubTimestamp":1773296740,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jiangsu Hengrui Pharmaceuticals  obtained approval from China's National Medical Products Administration for the clinical trial of SHR-9803 for injection, according to a Shanghai bourse filing on Thursday.The drug will be tested in combination with Adebrelimab, Bevacizumab and chemotherapy in patients with advanced malignant solid tumors.The pharmaceutical company's Hong Kong shares slipped over 1% during the afternoon trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK1191":"制药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","01276":"恒瑞医药","LU0359201612.USD":"贝莱德中国基金A2"},"translate_title":"恒瑞医药获得注射用SHR-9803试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":0.9},"content_text":"Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) obtained approval from China's National Medical Products Administration for the clinical trial of SHR-9803 for injection, according to a Shanghai bourse filing on Thursday.The drug will be tested in combination with Adebrelimab, Bevacizumab and chemotherapy in patients with advanced malignant solid tumors.The pharmaceutical company's Hong Kong shares slipped over 1% during the afternoon trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}